Singapore- Thermo Fisher Scientific has entered into agreements with Daiichi Sankyo and Takeda Pharmaceutical aimed at expanding the utility of its Oncomine Dx Target Test to support each firm's clinical trials and development programs.

Thermo Fisher, committed to advancing development of Oncomine Dx as a companion diagnostic for multiple drugs, will retain global commercialization rights to the test and lead all regulatory submissions.

It has also closed a similar CDx deal with Spectrum Pharmaceuticals to support poziotinib in NSCLC.

Last year, Thermo Fisher inked CDx agreements with Agios Pharmaceuticals and Blueprint Medicines.